Proficio Capital Partners LLC Buys New Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Proficio Capital Partners LLC acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 19,043 shares of the biopharmaceutical company's stock, valued at approximately $1,590,000.

Several other large investors have also made changes to their positions in ITCI. True Wealth Design LLC acquired a new stake in Intra-Cellular Therapies during the third quarter worth about $32,000. GAMMA Investing LLC lifted its stake in shares of Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 240 shares in the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of Intra-Cellular Therapies during the 3rd quarter worth about $74,000. Venturi Wealth Management LLC acquired a new stake in Intra-Cellular Therapies during the 4th quarter worth approximately $96,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in Intra-Cellular Therapies in the third quarter valued at approximately $97,000. 92.33% of the stock is owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Trading Up 0.0 %

NASDAQ:ITCI traded up $0.01 during mid-day trading on Monday, hitting $131.25. The stock had a trading volume of 2,622,858 shares, compared to its average volume of 3,735,314. The company has a 50 day simple moving average of $119.20 and a 200-day simple moving average of $93.68. The stock has a market capitalization of $13.96 billion, a price-to-earnings ratio of -150.86 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 52 week low of $63.30 and a 52 week high of $131.36.

Remove Ads

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. As a group, equities research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ITCI has been the subject of several recent research reports. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a report on Tuesday, January 14th. Baird R W lowered Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and boosted their price objective for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Finally, Needham & Company LLC restated a "hold" rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Ten investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Intra-Cellular Therapies presently has a consensus rating of "Hold" and an average target price of $106.08.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.